Inherited Variation in the ATP-Binding Cassette Transporter ABCB1 and Survival after Chemotherapy for Stage III–IV Lung Cancer  by Weissfeld, Joel L. et al.
1264 Journal of Thoracic Oncology ®  •  Volume 9, Number 9, September 2014
Background: The ATP-binding cassette transporter gene ABCB1 
and the glutathione S-transferase gene GSTP1 code for a multidrug 
resistance protein and for a detoxifying phase II metabolic enzyme, 
respectively, with substrate specificities that include chemotherapy 
drugs often used to treat lung cancer.
Methods: We genotyped 11 ABCB1 and eight GSTP1 single nucleo-
tide polymorphisms (SNPs) in 698 white lung cancer patients (all 
current or former cigarette smokers) and used log-rank test statistics 
and proportional hazards regression to evaluate associations between 
SNP genotype and survival.
Results: Using data from all 698 cases, one SNP in ABCB1 
(rs2235013) was statistically significantly associated with overall sur-
vival (p = 0.038, log-rank test). Chemotherapy and stage jointly (p = 
0.025) significantly modified the association between rs2235013 and 
survival, with statistically significant (p = 0.013, log-rank test) associ-
ation observed in the subgroup of stage III to IV lung cancer patients 
who received chemotherapy as part of their first course of treatment 
(n = 160; 93.1% nonsmall cell). Patients who inherited the minor T 
allele at ABCB1 rs2235013 experienced better overall survival and 
recurrence-free survival (hazard ratio, per minor T allele, [95% confi-
dence interval]: 0.66 [0.49–0.90] and 0.55 [0.31–0.95], respectively; 
adjusted for year of diagnosis, sex, age at diagnosis, cigarette pack 
years, and stage). In addition, in the advanced stage chemother-
apy-treated subgroup, four ABCB1 SNPs (rs6949448, rs2235046, 
rs1128503, and rs10276036) in mutual high linkage disequilibrium 
with rs2235013 and an independent ABCB1 SNP (rs1045642) showed 
statistically significant association (p < 0.05) with survival.
Conclusions: Inherited variation in ABCB1 may affect survival specifi-
cally in advanced stage lung cancer patients who receive chemotherapy.
(J Thorac Oncol. 2014;9: 1264–1271)
The Surveillance, Epidemiology, and End Results (SEER) Program gathers population-based cancer occurrence data 
for the US population. Among persons diagnosed between 
2004 and 2009 with lung cancer as their first lifetime can-
cer diagnosis, SEER placed 87% in a non–small-cell histo-
logic category and 87% of these non–small-cell cases in an 
American Joint Committee on Cancer sixth edition stage 
IIIA, IIIB, or IV group.1 One year after diagnosis, only 31% 
of these persons with advanced non–small lung cancer were 
still alive.1 Two decades ago, modern chemotherapy regimens 
that contain cisplatin were known to somewhat improve the 
survival of patients with advanced non–small-cell lung can-
cer.2 However, treatment-related toxicities, combined with the 
weak-survival benefits typically observed, continue to moti-
vate efforts to identify lung cancer patients who experience 
particularly favorable responses to multiagent chemotherapy. 
One research approach attempts to associate inherited factors, 
including inherited factors governing drug metabolism, with 
treatment response.
To evaluate inherited variation in DNA repair and cell 
cycle control pathway genes in relation to lung cancer risk, we 
designed and completed a large case-control study of white cur-
rent and former cigarette smokers with and without incident lung 
cancer.3 Anticipating subsequent investigation in our lung cancer 
case series of factors related to treatment outcome, we included 
ATP-binding cassette, subfamily B, member 1 gene (ABCB1), 
and glutathione S-transferase gene pi 1 (GSTP1) single nucleo-
tide polymorphisms (SNPs) on a custom-designed 384-SNP 
microarray used to genotype all cases and controls. ABCB1 
and GSTP1 code for a multidrug resistance (MDR) protein and 
detoxifying phase II metabolic enzyme, respectively, both agents 
engaged in the metabolism of chemotherapy drugs often used 
in lung cancer.4,5 Genotyping all patients permitted study of the 
specificity of association between inherited variants and clini-
cal outcome. We expected outcome associations with inherited 
variation in ABCB1 or GSTP1 to seem more prominently among 
patients exposed to chemotherapy. After screening all cases for 
modification by chemotherapy of the association between inher-
ited variation and outcome, we restricted analysis to late-stage 
chemotherapy cases and evaluated lung cancer survival out-
comes in relation to inherited variation in ABCB1 and GSTP1, 
genes that participate in the metabolism of two often used lung 
cancer chemotherapeutics, taxanes and platinum, respectively.
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PATIENTS AND METHODS
Study Population
Patients were enrolled between 1990 and 2008 within 1 
year of a thoracic surgery procedure for lung cancer diagno-
sis, staging, or treatment at a University of Pittsburgh Medical 
Center (UPMC) hospital. Additional eligibility criteria for the 
current study included (1) white race (as documented in the 
UPMC Network Cancer Registry), (2) current or ex-cigarette 
smoker, (3) more than 10 pack-year cumulative cigarette dose 
exposure (pack years), (4) 45- to 85-years old at the time of 
lung cancer diagnosis, (5) pathologically verified lung cancer 
diagnosis (excluding carcinoid), and (6) DNA sample avail-
able for genotyping. In total, 782 patients fulfilled these crite-
ria. All patients provided written informed consent and were 
enrolled under University of Pittsburgh Institutional Review 
Board–approved protocols.
Tumor Histology, Cancer Stage, 
Treatment, and Outcome
To determine primary tumor histology, cancer stage, 
first course of treatment, and survival outcomes, we linked 
research patient data to the Cancer Registry. Analyses classed 
primary tumor ICD-O-3 histologic type codes6 into four 
broad groupings representing adenocarcinoma and bron-
chioloalveolar carcinoma, squamous cell carcinoma, small-
cell carcinoma, and other non–small cell types, including 
non–small-cell carcinoma (not otherwise specified), large-
cell carcinoma, and adenosquamous carcinoma. Analyses 
defined the anatomic extent of disease at diagnosis according 
to American Joint Committee on Cancer pathologic tumor, 
node, metastasis stage grouping, if defined, or clinical tumor, 
node, metastasis stage grouping, otherwise, in effect at the 
time of diagnosis (third, fourth, fifth, and sixth editions for 
cases diagnosed in 1990–1991, 1992–1997, 1998–2002, and 
2003–2008,7 respectively). Cancer Registry results coded 
according to North American Association of Central Cancer 
Registries standards8,9 identified patients administered pre or 
postadjuvant chemotherapy as part of the first course of treat-
ment, before disease progression or recurrence. To identify 
affirmatively the subset of patients who received platinum 
(cisplatin or carboplatin) or taxane (paclitaxel or docetaxel) 
chemotherapy, we decoded the free text field used by cancer 
registrars to document chemotherapy. Overall survival and 
recurrence-free survival were calculated as time from ini-
tial diagnosis to death and time from initial diagnosis to first 
recurrence, respectively, with follow-up censored on the date 
of last contact. Analyses of recurrence-free survival excluded 
patients who never became disease-free after diagnosis.
Patients without a matching lung tumor record in the 
Cancer Registry (n = 10, 1.3% of 782) and patients with a 
matching lung tumor record that lacked values for lung tumor 
histology, stage, and/or treatment (n = 29, 3.7% of 782) were 
excluded. Histologies other than adenocarcinoma or squa-
mous cell carcinoma were more frequent among excluded 
than included patients. Excluded and included patients were 
statistically similar (p > 0.15) with respect to sex, age at diag-
nosis, year of diagnosis, pack years, and stage.
SNP Selection
Priority was given to SNPs with the following attri-
butes: (1) functional significance as determined by amino acid 
substitution; (2) potential for regulatory change; (3) predicted 
alteration in protein stability; (4) evolutionary conservation 
across species; (5) disease association reported in the litera-
ture, and (6) genotyping feasible with Illumina GoldenGate 
Assay (Illumina Inc, San Diego, CA) technology. In total, we 
selected 12 SNPs in ABCB1 and 9 in GSTP1.
DNA Isolation and Genotyping
Genomic DNA was isolated using Gentra Systems, 
Inc. (Minneapolis, MN) isolation kits and genotyped using 
an Illumina GoldenGate custom-designed 384-SNP micro-
array. Analyses serially excluded (1) assigned genotypes by 
Illumina GenomeStudio 2010.1 using a GenTrain score less 
than 0.45 or a ClusterSep score less than 0.25; (2) individuals 
with genotype call rates less than 95% (calculated using all 
SNPs covered by the 384-SNP microarray, including SNPs in 
genes other than ABCB1 and GSTP1); (3) SNPs that failed in 
more than 2% of the samples; and (4) SNPs with minor allele 
frequency (MAF) less than 5%. After excluding 45 patients 
(6.1% of 743 patients with complete Cancer Registry data) 
for call rates less than 95%, 698 patients remained for analy-
sis. Women were excluded more often than men (7.9% versus 
4.5%, p = 0.0548) because of low-call rates. Excluded and 
included patients were statistically similar (p > 0.45) with 
respect to age at diagnosis, year of diagnosis, pack years, 
stage, and exposure to any chemotherapy as part of first 
planned course of treatment. After excluding one ABCB1 
SNP (rs1015415) that failed in more than 2% of samples and 
one GSTP1 SNP (rs8191438) with MAF less than 5%, 11 
ABCB1 and eight GSTP1 SNPs remained. We assessed these 
11 ABCB1 and eight GSTP1 SNPs for association with sur-
vival, although two GSTP1 SNPs departed (p < 0.01) from 
Hardy–Weinberg Equilibrium when evaluated separately in 
our 698 study patients and in 929 white control subjects from 
our earlier study (Supplemental Table 1, Supplemental Digital 
Content, http://links.lww.com/JTO/A628).3 The 11 SNPs in 
ABCB1 and eight SNPs in GSTP1 captured (at r2 > 0.80) 58% 
(52 of 89 alleles) and 72% (18 of 25 alleles), respectively, 
of the common-variant CEU SNPs in these genes (MAF > 
5% in HapMap Genome Browser release no. 28 [phases 1, 
2, and 3], ABCB1—chr7:86,950,884..87,190,500, GSTP1—
chr11:67,087,862..67,120,699; http://hapmap.ncbi.nlm.nih.
gov/). All SNP alleles in this manuscript are reported in for-
ward orientation with respect to the genome.
Statistical Analysis
We used χ2 tests to evaluate independence between gen-
otype and clinical factors, such as treatment and stage, the 
Kaplan-Meier method to estimate survival functions, and the 
log-rank test with a Wilcoxon weight (the number at risk n
i
 at 
failure time t
i
) to compare survival differences according to 
genotype. Using SAS 9.2 (PROC PHREG), we fit Cox propor-
tional hazards models to control genotype-outcome associa-
tions for potential confounders and applied a log-likelihood 
ratio test to genotype by cofactor interaction terms to screen 
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for effect modification. To detect departures from the propor-
tional hazards assumption, we examined Schoenfeld residual 
plots and tested the statistical significance of terms represent-
ing the time-dependent interaction between genotype and the 
natural logarithm of survival time. We fit additive genetic 
models with the common allele as reference.
Haplotype-based analyses used the expectation-max-
imization algorithm implemented in SAS Genetics (PROC 
HAPLOTYPE) to estimate group-level haplotype frequencies 
and to generate subject-level haplotype probability weights 
(http://support.sas.com/documentation/cdl/en/geneug/59659/
HTML/default/geneug_haplotype_sect021.htm). We used 
these haplotype probability weights and Cox regression to 
identify haplotypes independently associated with survival.
RESULTS
Characteristic of the study population (n = 698) are pre-
sented in Table 1. Our study population included n = 160 stage 
III to IV patients who received chemotherapy, the subgroup 
most expected to experience different outcomes according to 
variation in ABCB1 or GSTP1. Although diverse with respect 
to sex, age, and pack years, the patients in this subgroup 
were characterized by diagnosis between 2000 and 2008, 
non–small-cell histology, and initial treatment with a chemo-
therapeutic regimen that included both platinum and taxane 
(Table 1). Our study population also included n = 470 stage 
I to II patients (n = 362 not given chemotherapy and n = 108 
given chemotherapy) and n = 68 stage III to IV patients not 
given chemotherapy.
We first used all n = 698 patients to screen for the fol-
lowing: (1) chemotherapy/stage independence from SNP 
genotype, (2) association (without and with control for che-
motherapy/stage) between genotype and survival, and (3) 
modification by chemotherapy/stage of association between 
genotype and survival. Results are presented in Supplemental 
Table 2 (Supplemental Digital Content, http://links.lww.com/
JTO/A628). Chemotherapy (administered versus not adminis-
tered), stage (I–II versus III–IV), and chemotherapy and stage 
jointly were independent of all evaluated ABCB1 and GSTP1 
SNPs. One SNP in ABCB1 (rs2235013) showed a statisti-
cally significant association with overall survival (p = 0.038, 
Wilcoxon-weighted log-rank test). This statistically significant 
association persisted in Cox regression controlled for stage 
(p = 0.041). Notably, stage (p = 0.001) and chemotherapy and 
stage jointly (p = 0.025) significantly modified the association 
between rs2235013 genotype and survival.
Figure 1 explicates the modifying effect of chemo-
therapy/stage on association between rs2235013 and survival. 
Kaplan-Meier overall survival plots were qualitatively and sta-
tistically similar according to rs2235013 genotype in stage I 
to II patients not given chemotherapy, in stage I to II patients 
given chemotherapy, and in stage III to IV patients not given 
chemotherapy. However, in stage III to IV patients given che-
motherapy, overall survival was relatively poor, in-between, 
and favorable in patients who inherited rs2235013 CC, CT, 
and TT, respectively (p = 0.013). Among chemotherapy-
treated stage III to IV patients who became disease-free after 
diagnosis, recurrence-free survival also differed according 
to rs2235013 genotype, with recurrence-free survival more 
favorable among 13 T-allele homozygotes than 60 heterozy-
gotes and 20 C-allele homozygotes (p = 0.034).
Using Cox regression to control for year of diagnosis 
(1990–1999/2000–2008), sex (men/women), age at diagnosis 
(<55/55–64/65–69/70–74/75+), pack years (<35/35–49/50–
74/75+), and stage (III/IV), stage III to IV patients given chemo-
therapy experienced a statistically significant (p = 0.009) overall 
survival benefit in association with the ABCB1 rs2235013 T 
allele (hazard ratio [HR] [per T allele] 0.66, 95% confidence 
interval [CI] 0.49–0.90; Table 2). As shown in Table 2, statisti-
cally significant (p < 0.05) overall survival differences were also 
observed in association with five other ABCB1 SNPs but not 
in association with any GSTP1 SNPs. These conclusions were 
unaffected by the addition of surgical therapy or radiation ther-
apy to our multivariable models (data not shown). Supplemental 
Figure 1 (Supplemental Digital Content, http://links.lww.com/
JTO/A628) shows an ABCB1 linkage disequilibrium (LD) 
plot for our stage III to IV lung cancer patients given chemo-
therapy. Five survival-associated SNPs (rs6949448, rs2235046, 
rs1128503, and rs10276036, in addition to rs2235013) were in 
high LD (r2 > 0.80) with each other.
We examined SNP associations with overall sur-
vival in a subgroup (n = 106) of advanced stage non–small-
cell lung cancer patients who received standard treatment, 
defined to include multiagent chemotherapy (North American 
Association of Central Cancer Registries Item no. 1390 code 
03) that included both platinum (carboplatin or cisplatin), 
taxane, and possibly other agents. Compared with results 
observed in all stage III to IV patients given chemotherapy, 
results observed in stage III to IV non–small-cell lung cancer 
patients documented to have received standard treatment were 
similar in both direction and magnitude. In this subgroup, one 
SNP retained its statistically significant association with over-
all survival (rs2235046, adjusted HR 1.58, 95% CI 1.01–2.48, 
p = 0.047; Table 2). ABCB1 differences observed with respect 
to overall survival among all chemotherapy-treated stage III to 
IV patients were also observed with respect to recurrence-free 
survival among chemotherapy-treated stage III to IV patients 
who became disease-free after diagnosis (Table 2).
Pharmacogenomic studies have frequently consid-
ered haplotypes formed from three ABCB1 SNPs, rs1045642 
(3435C>T, Ile1145Ile), rs2032582 (2677G>TA, Ala893Ser/
Thr), and rs1128503 (1236C>T, Gly412Gly).10 Our SNP 
panel included the first and third SNP, two survival-associ-
ated SNPs among stage III to IV cases given chemotherapy 
(Table 2). Limitations of the Illumina GoldenGate technology 
did not allow us to genotype rs2032582. However, we geno-
typed rs2235046, a survival-associated (Table 2) intronic SNP 
in high LD with rs2032582 (r2 = 0.94, HapMap CEU popu-
lation). Substituting rs2235046 for rs2032582, we estimated 
rs1045642–rs2235046–rs1128503 haplotype probability 
weights and entered these weights jointly into Cox regression 
models. Referenced against the common GCG haplotype, hap-
lotypes containing T at rs2235046 and A at rs1128503 signi-
fied poorer overall survival (per ATA allele: adjusted HR 1.46, 
95% CI 1.05–2.03; per GTA allele: adjusted HR 2.19, 95% CI 
1.06–4.52; Table 3). Statistically significant survival differences 
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were not observed for the haplotype containing A at rs1045642 
(per ACG allele: adjusted HR 1.18, 95% CI 0.77–1.82).
DISCUSSION
We systematically evaluated 11 ABCB1 and eight 
GSTP1 SNPs for survival differences in 698 white lung 
cancer patients. Five ABCB1 SNPs in high LD (rs6949448, 
rs2235046, rs2235013, rs1128503, and rs10276036) and a 
sixth independent ABCB1 SNP (rs1045642) showed statisti-
cally significant and specific associations with survival out-
comes in patients with advanced lung cancer managed with 
chemotherapy. We did not observe statistically significant sur-
vival differences according to inherited variation in GSTP1.
GSTP1 codes for a detoxifying phase II metabolic 
enzyme that conjugates reduced glutathione to many xeno-
biotic compounds, including platinum-containing cancer 
drugs.4 ATP-binding cassette, subfamily B (MDR/TAP), 
member 1 (ABCB1) codes for the multidrug resistance pro-
tein, P-glycoprotein 1, a membrane-associated protein that 
transports many xenobiotic compounds from the cytoplasm to 
the extracellular space. ABCB1 and three other ATP-binding 
cassette genes (ABCG2, ABCC1, and ABCC2) participate in 
the intra- to extracellular transport of taxane chemotherapeu-
tics.5 Inherited variation in these genes may affect treatment 
response and survival. By 1990, the start of enrollment for 
our study, multimodality treatments that included platinum 
TABLE 1.  Characteristics of the Study Population (n = 698), by Stage and Chemotherapy Administration
Characteristic
Stage I–II Stage III–IV
OverallNo Chemotherapy Yes Chemotherapy No Chemotherapy Yes Chemotherapy
n (%) n (%) n (%) n (%) n (%)
All 362 (100.0) 108 (100.0) 68 (100.0) 160 (100.0) 698 (100.0)
Sex
  Men 183 (50.6) 67 (62.0) 44 (64.7) 88 (55.0) 382 (54.7)
  Women 179 (49.4) 41 (38.0) 24 (35.3) 72 (45.0) 316 (45.3)
Age (yr) at diagnosis
  <55 21 (5.8) 11 (10.2) 2 (2.9) 29 (18.1) 63 (9.0)
  55–64 86 (23.8) 44 (40.7) 17 (25.0) 44 (27.5) 191 (27.4)
  65–69 91 (25.1) 23 (21.3) 14 (20.6) 30 (18.8) 158 (22.6)
  70–74 70 (19.3) 21 (19.4) 15 (22.1) 28 (17.5) 134 (19.2)
  75+ 94 (26.0) 9 (8.3) 20 (29.4) 29 (18.1) 152 (21.8)
Year of diagnosis
  1990–1999 147 (40.6) 14 (13.0) 40 (58.8) 27 (16.9) 228 (32.7)
  2000–2008 215 (59.4) 94 (87.0) 28 (41.2) 133 (83.1) 470 (67.3)
Pack years
  <35 99 (27.3) 30 (27.8) 15 (22.1) 36 (22.5) 180 (25.8)
  35–49 57 (15.7) 18 (16.7) 14 (20.6) 40 (25.0) 129 (18.5)
  50–74 108 (29.8) 33 (30.6) 24 (35.3) 47 (29.4) 212 (30.4)
  75+ 98 (27.1) 27 (25.0) 15 (22.1) 37 (23.1) 177 (25.4)
Histology grouping
  Adenocarcinoma/BAC 187 (51.7) 41 (38.0) 29 (42.6) 76 (47.5) 333 (47.7)
  Squamous cell 143 (39.5) 42 (38.9) 31 (45.6) 52 (32.5) 268 (38.4)
  Other non–small-cell carcinoma 31 (8.6) 18 (16.7) 8 (11.8) 21 (13.1) 78 (11.2)
  Small-cell carcinoma 1 (0.3) 7 (6.5) 0 (0.0) 11 (6.9) 19 (2.7)
Chemotherapy1
  Single or multiple agents 97 (89.8) 146 (91.2)
   Platinum and taxane 72 (66.7) 111 (69.4)
   Platinum only 15 (13.9) 29 (18.1)
   Taxane only 5 (4.6) 3 (1.9)
   Neither 5 (4.6) 3 (1.9)
  Chemotherapy, NOS 11 (10.2) 14 (8.8)
Surgical therapy 360 (99.4) 102 (94.4) 62 (91.2) 103 (64.4) 627 (89.8)
Radiation therapy 44 (12.2) 53 (49.1) 19 (27.9) 98 (61.3) 214 (30.7)
1. First-order (no chemotherapy vs. chemotherapy, NOS vs. single or multiple agent chemotherapy) classification based on NAACCR Item no. 1390 and second-order classification 
(platinum and taxane vs. platinum only vs. taxane only vs. neither) classification based on chemotherapy exposures documented in NAACCR Item no. 2640 free text field. The second-
order classification disregards documented exposures to agents other than platinum or taxane.
BAC, bronchioloalveolar carcinoma; NAACCR, North American Association of Central Cancer Registries.
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were known to improve the survival of patients with locally 
advanced (stage III)11 and advanced (stage IV)12 non–small-
cell lung cancer. Subsequent developments soon established 
multiagent chemotherapy, combining platinum with second 
agents, frequently taxanes, as standard primary treatments for 
advanced non–small-cell lung cancer.11,12 Our study sample 
included 11 and 217 advanced stage small and non–small-cell 
lung cancer cases, respectively (Table 1). All 11 small-cell 
and 149 non–small-cell cases received chemotherapy as 
part of primary treatment, with exposure to both platinum 
and taxane documented in 111 (49% of 228 advanced stage 
cases). These results not only establish taxane, in our sample, 
as the preferred second agent to combine with platinum for 
treatment of advanced non–small-cell lung cancer but also 
create opportunity to observe variable outcomes in relation 
to an inherited factor that affects cellular delivery of taxane 
FIGURE 1.  Overall and recurrence-
free survival (Kaplan-Meier plots, 
showing sample counts and statistical 
significance according to Wilcoxon-
weighted log-rank test p-values) for 
each of 4 lung cancer subgroups: 
stage I-II not given chemotherapy, 
stage I-II given chemotherapy, stage 
III-IV not given chemotherapy, and 
stage III-IV given chemotherapy, 
according to ABCB1 rs2235013 
genotype (CC in black, CT in solid 
gray, and TT in dashed gray). Plus 
("+") symbols signify censored 
observations.
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chemotherapeutics. In this context, survival associations 
with the ABCB1 SNPs of interest were preserved, although 
at reduced levels of statistical significance, in the smaller set 
of advanced non–small-cell lung cancer patients with docu-
mented exposures to both platinum and taxane.
A literature search for studies of lung cancer outcomes 
in relation to inherited variability in ABCB1 produced 10 
results,13–22 many included in a 2011 metaanalysis.23 The nine 
earliest studies,13–20,22 from the United States,16 Europe,13,19,22 
and Asia,14–18,20 examined no more than three ABCB1 vari-
ants, most often rs1045642 (3435C>T, Ile1145Ile). The lim-
ited evidence provided by these small studies, each containing 
between 5417 and 10714 cases of advanced (stage IIIB–IV) 
non–small-cell lung cancer, suggest, consistent with our 
results, better tumor response in patients homozygous for the 
ABCB1 3435C allele, which corresponds to the rs1045642 G 
TABLE 2.   Results from Cox Proportional Hazards Regression Models: SNP Associations with Overall and Recurrence-Free 
Survival (Additive Genetic Model; Stage III–IV, Chemotherapy-Administered Subgroup), Adjusted for Year of Diagnosis (1990–
1999/2000–2008), Sex (Men/Women), Age at Diagnosis (<55/55–64/65–69/70–74/75+), Pack Years (<35/35–49/50–74/75+), 
and Stage (III/IV)
SNP Allelesa
Overall Survival Recurrence-Free Survival3
All Subjects Standard Treatmentb Disease-Free Postdiagnosis
N HR 95% CI p Value N HR 95% CI p Value N HR 95% CI p Value
ABCB1
  rs1045642 A/G 160 0.77 0.59–0.99 0.045 106 0.74 0.50–1.09 0.126 93 0.62 0.38–1.00 0.050
  rs6949448 C/T 160 1.47 1.06–2.03 0.020 106 1.37 0.86–2.18 0.186 93 1.91 1.05–3.49 0.034
  rs2235067 C/T 160 0.75 0.48–1.10 0.141 106 0.67 0.38–1.10 0.116 93 0.54 0.21–1.11 0.098
  rs2235046 C/T 160 1.54 1.12–2.11 0.008 106 1.58 1.01–2.48 0.047 93 1.85 1.01–3.39 0.045
  rs2235013 C/T 160 0.66 0.49–0.90 0.009 106 0.67 0.44–1.02 0.062 93 0.55 0.31–0.95 0.032
  rs2235035 G/A 159 0.89 0.64–1.22 0.463 105 0.91 0.59–1.40 0.680 93 0.85 0.47–1.55 0.584
  rs1128503 G/A 160 1.53 1.11–2.09 0.009 106 1.51 0.96–2.37 0.075 93 2.04 1.11–3.77 0.021
  rs10276036 T/C 160 1.53 1.11–2.09 0.009 106 1.51 0.96–2.37 0.075 93 2.04 1.11–3.77 0.021
  rs1922240 T/C 160 0.87 0.62–1.20 0.383 106 0.87 0.57–1.34 0.542 93 0.85 0.47–1.55 0.584
  rs1202179 T/C 160 0.79 0.58–1.06 0.117 106 0.85 0.57–1.25 0.413 93 0.69 0.38–1.18 0.181
  rs4728709 G/A 160 0.64 0.32–1.15 0.144 106 0.71 0.27–1.53 0.408 93 0.78 0.28–1.76 0.582
GSTP1
  rs6591256 A/G 160 0.95 0.73–1.24 0.725 106 1.10 0.76–1.57 0.615 93 0.79 0.50–1.24 0.303
  rs17593068 G/T 160 0.95 0.72–1.25 0.726 106 1.13 0.78–1.63 0.507 93 0.83 0.51–1.32 0.429
  rs4147581 G/C 160 1.10 0.84–1.44 0.474 106 1.41 0.98–2.03 0.067 93 0.90 0.57–1.44 0.673
  rs762803 C/A 159 0.95 0.72–1.24 0.699 106 1.13 0.78–1.63 0.507 92 0.87 0.53–1.40 0.568
  rs1695 A/G 160 0.91 0.68–1.22 0.535 106 1.10 0.73–1.66 0.639 93 0.66 0.38–1.12 0.126
  rs1138272 C/T 160 1.06 0.62–1.75 0.819 106 1.32 0.60–2.66 0.474 93 0.42 0.12–1.09 0.078
  rs4891 T/C 160 0.99 0.68–1.46 0.965 106 1.24 0.70–2.19 0.461 93 0.73 0.34–1.54 0.418
  rs947895 C/A 159 0.87 0.65–1.17 0.374 105 1.08 0.71–1.64 0.720 93 0.76 0.44–1.29 0.317
aCommon/minor allele.
bRestricted to stage III–IV non–small- cell lung cancer cases who received planned multiagent chemotherapy first course of treatment with exposure to platinum (carboplatin or 
cisplatin) and taxane documented.
cFifty-two (52) patients remaining disease free over a median postdiagnosis 4.0-year follow-up period (interquartile range 1.4–6.3 years).
HR, hazard ratio; CI, confidence interval; P statistical significance (p value).
TABLE 3.  Results from Cox Proportional Hazards Regression Models: Joint rs1045642–rs2235046–rs1128503 Haplotype 
(Additive Genetic Model) Association with Overall Survival (White Race, Stage III–IV, Chemotherapy Administered, n = 160)
Haplotype Freq
Unadjusted Adjusteda
HR 95% CI p Value HR 95% CI p Value
GCG 0.46 REF REF
ATA 0.39 1.54 1.14–2.09 0.006 1.46 1.05–2.03 0.023
ACG 0.11 1.22 0.80–1.86 0.353 1.18 0.77–1.82 0.446
GTA 0.04 2.42 1.21–4.83 0.012 2.19 1.06–4.52 0.035
aAdjusted for year of diagnosis (1990–1999/2000–2008), sex (men/women), age at diagnosis (<55/55–64/65–69/70–74/75+), pack years (<35/35–49/50–74/75+), and stage (III/IV).
Freq, estimated haplotype frequency; HR, hazard ratio (per allele); CI, confidence interval.
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allele in our study. No SNP in ABCB1 or GSTP1 passed initial 
screens of genome-wide association with advanced lung can-
cer survival after chemotherapy in Japanese (n = 105,),24 US 
Caucasian (n = 327),25 or Han Chinese (n = 528)26 populations.
Genotyping 206 and 171 Caucasian Germans with 
stage II to IV non–small-cell and small-cell lung cancer (75% 
platinum treated), respectively, Campa et al.21 recently pub-
lished results from a systematic study of tumor response, pro-
gression-free survival, and overall survival in relation to 25 
ABCB1, 12 ABCC2, and 16 ABCG2 haplotype tagging SNPs. 
The most statistically significant result appeared in small-cell 
lung cancer patients treated with platinum (n = 126), where 
ABCC2 rs717620 minor allele containing genotypes por-
tended poorer progression-free survival (sex-, age-, and stage-
adjusted HR 1.95, 95% CI 1.29–2.94, p = 0.0015). Campa 
et al.21 also called attention to statistically significant asso-
ciations between inherited variations in ABCB1 rs6979885 
and survival in patients with small-cell lung cancer. Using 
HapMap CEU data, rs6979885 did not link with any of the 11 
SNPs in our ABCB1 panel. Two SNPs in our panel, rs1045642 
and rs2235013, were also evaluated by Campa et al.21 In our 
study population, the rs1045642 and rs2235013 minor alleles 
were associated with better survival. In line with our results, 
Campa et al.21 reported better survival (p < 0.05) in small-cell 
lung cancer patients who inherited the rs1045642 G allele and 
in both small-cell and non–small-cell patients who inherited 
the rs2235013 T allele.
Our result showing association between inherited varia-
tion in ABCB1 and survival in lung cancer patients, the majority 
having received taxane (Table 2), is consistent with the observa-
tion that ABCB1 transports taxane out of cells.5 Because our 
patients almost always received taxane in combination with 
platinum, we could not separately determine the association 
between ABCB1 and survival in patients who received only plat-
inum or only taxane. Cisplatin and carboplatin are not substrates 
for the ABCB1 transporter,27,28 which argues against a contri-
bution from these agents to the survival effects we observed. 
However, a recent study identified a novel ABCB1 transporter 
function, caspase-3 blockade, a mechanism whereby variation 
in ABCB1 might explain cisplatin resistance.29 Another report 
connected down-regulation of ABCB1 with reversal of cisplatin 
resistance in cervical cancer cells.30
Our white only patient sample enabled study of asso-
ciations between inherited differences and survival, specific 
to stage (stage I–II versus stage III–IV) and chemotherapy as 
part of first course of treatment. Notwithstanding absent infor-
mation about drug dosages and number of completed cycles, 
our study was not able, as noted above, to differentiate SNP 
effects specific to type of chemotherapy, taxane versus plati-
num. SNPs were primarily selected based on biological plau-
sibility, and not all common variation in ABCB1 and GSTP1 
was evaluated. It is possible that important associations and/
or interactions were not identified due to the limited number 
of SNPs investigated. Nominal p values shown in Table 2 and 
elsewhere do not correct for multiple comparisons. In addi-
tion, sample size prohibited study of rare gene variants. We 
determined recurrence-free survival from clinical sources 
where monitoring for recurrence did not occur according to a 
fixed protocol. Lacking information about gene expression or 
function in tumor or host tissues, we can only speculate about 
the biological significance of our observations. An influential 
study, published in 2000,31 attributed functional significance to 
rs1045642, a synonymous polymorphism in ABCB1 exon 26. 
More recent critical reviews find only inconsistencies in the 
literature with respect to the effects of ABCB1 genotypes on 
MDR protein expression or function.10,32 The absence of repro-
ducible findings regarding the clinical significance of indi-
vidual ABCB1 SNPs motivates study of ABCB1 haplotypes.32 
Our analysis of 3-SNP haplotypes formed with often studied 
variants (Table 3) concurs with results from single SNP analy-
sis (Table 2). In this context, a recent study observed strong 
association between similarly constructed three-variant hap-
lotypes and imatinib response in chronic myeloid leukemia.33
In conclusion, partially validating findings in an inde-
pendent patient population,21 we observed statistically sig-
nificant associations between inherited variation in ABCB1 
and clinical outcomes in advanced stage lung cancer patients 
treated with chemotherapy.
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